Skip to content
mapperlab
← Dashboard
Stock

ALT

Altimmune, Inc.
Latest close $2.806 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
6
27 funds tracked
Ever held
6
Current + past
New this quarter
1
Exited this quarter
0

Marquee-fund ownership over time

Aug 14, 2024Aug 14, 2025Feb 17, 2026May 15, 2026
Now
6

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors re-entered$6.18$2.80-55%
Two Sigma Investments$6.18$2.80-55%
D.E. Shaw$6.18$2.80-55%
AQR Capital Management re-entered$6.18$2.80-55%
Millennium Management$6.18$2.80-55%
Point72 Asset Management re-entered$4.17$2.80-33%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Altimmune, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
11
Filings · last 90d
18
Total on file
434
Recent SEC buffer
Most recent
May 1, 2026

30d / 90d windows measured from May 1, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 434 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Altimmune, Inc.

Annual figures sourced directly from Altimmune, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$41K
FY2025+105% YoY
Net income
-$88.09M
FY2025+7% YoY
EPS (diluted)
$-1.00
FY2025+25% YoY
Free cash flow(?)
-$67.55M
FY2025+15% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Altimmune, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Point72 Asset ManagementQ2 2026open$2.85$2.80-2%
AQR Capital ManagementQ1 2026open$4.50$2.80-38%
Point72 Asset ManagementQ4 2025Q1 2026$4.17$4.50+8%
Citadel AdvisorsQ3 2025open$3.68$2.80-24%
Citadel AdvisorsQ3 2024Q2 2025$6.18$5.78-6%
Two Sigma InvestmentsQ3 2024open$6.18$2.80-55%
D.E. ShawQ3 2024open$6.18$2.80-55%
AQR Capital ManagementQ3 2024Q2 2025$6.18$5.78-6%
Millennium ManagementQ3 2024open$6.18$2.80-55%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.